Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells

The Lancet Pub Date : 2025-02-27 DOI:10.1016/s0140-6736(25)00039-x

Daniel J Baker, Bruce L Levine, Carl H June

{"title":"Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells","authors":"Daniel J Baker, Bruce L Levine, Carl H June","doi":"10.1016/s0140-6736(25)00039-x","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>DJB led the conceptualisation and writing of the original draft. All authors provided comments and edits of subsequent drafts. All authors approved the final manuscript and had final responsibility for the decision to submit for publication.</section></section><section><section><h2>Declaration of interests</h2>BLL is an inventor on patents or has patent applications licensed to Novartis Institutes of Biomedical Research and Kite Pharma and receives licence revenue from such licences; is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics; and is a member of the scientific advisory boards of Avectas, Capstan Therapeutics, Cellula Therapeutics, Immuneel Therapeutics, Immusoft, In8bio, Kite Gilead, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics. CHJ</section></section><section><section><h2>Acknowledgments</h2>This work was supported by the Centurion Foundation Innovation Fund (1P01CA214278, R01CA226983) and the Parker Institute for Cancer Immunotherapy. The funders had no role in the writing of the manuscript or the decision to submit for publication.</section></section>","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)00039-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Contributors

DJB led the conceptualisation and writing of the original draft. All authors provided comments and edits of subsequent drafts. All authors approved the final manuscript and had final responsibility for the decision to submit for publication.

Declaration of interests

BLL is an inventor on patents or has patent applications licensed to Novartis Institutes of Biomedical Research and Kite Pharma and receives licence revenue from such licences; is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics; and is a member of the scientific advisory boards of Avectas, Capstan Therapeutics, Cellula Therapeutics, Immuneel Therapeutics, Immusoft, In8bio, Kite Gilead, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics. CHJ

Acknowledgments

This work was supported by the Centurion Foundation Innovation Fund (1P01CA214278, R01CA226983) and the Parker Institute for Cancer Immunotherapy. The funders had no role in the writing of the manuscript or the decision to submit for publication.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估致癌风险：自体嵌合抗原受体T细胞的长期安全性

章节片段贡献者sdjb领导了原始草案的概念化和编写。所有作者都提供了对后续草稿的评论和编辑。所有作者都同意最终稿件，并对提交发表的决定负有最终责任。sll是专利发明人，或拥有向诺华生物医学研究所和Kite Pharma授权的专利申请，并从这些许可中获得许可收入；是社区治疗和Capstan治疗的科学创始人；他是Avectas、Capstan Therapeutics、Cellula Therapeutics、Immuneel Therapeutics、Immusoft、In8bio、Kite Gilead、Ori Biotech、Oxford Biomedica、ThermoFisher Pharma Services和UTC Therapeutics的科学顾问委员会成员。本研究得到了百夫长基金会创新基金（1P01CA214278, R01CA226983）和帕克癌症免疫治疗研究所的支持。资助者在撰写稿件或决定是否提交发表方面没有任何作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

The Lancet

自引率

0.00%

发文量